CureVac B.V

CureVac BV is a clinical-stage biopharmaceutical company, which engages in developing transformative medicines based on messenger ribonucleic acid (mRNA). Its product portfolio includes clinical and preclinical candidates across multiple disease indications in prophylactic vaccines, oncology, and protein therapy. The company was founded by Ingmar Hoerr and Florian von der Mülbe in 2000 and is headquartered in Tübingen, Germany.

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Acquisition extends CureVac's capabilities and adds key competencies to further accelerate oncology strategy for new therapies that enable patients' immune systems to fight cancer Frame's platform offers potential to develop off-the-shelf and personalized cancer vaccines targeting novel families of neoantigens TÜBINGEN, GERMANY and AMSTERDAM, NETHERLANDS / ACCESSWIRE / June 8, 2022 / CureVac N.V. (NASDAQ:CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced its acquisition of Frame Cancer Therapeutics, a private company focused on advanced genomics and bioinformatics to identify both unique and shared neoantigens across different cancer types.

CureVac Accelerates Oncology Strategy with Acquisition of Frame Cancer Therapeutics, Adding Novel Antigen Discovery Platform

Myriam Mendila appointed as Chief Development Officer starting from February 1, 2023 Klaus Edvardsen returning to Denmark after holding numerous leadership positions in the U.S. and Europe Ulrike Gnad-Vogt, Senior Vice President Area Head Oncology, will act as interim Chief Development Officer TÜBINGEN, DEUTSCHLAND and BOSTON, MA / ACCESSWIRE / June 8, 2022 / CureVac N.V. (NASDAQ:CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA") today announced that Chief Development Officer Klaus Edvardsen will leave the company on June 30, 2022.

CureVac Announces Changes of CDO - Myriam Mendila to Succeed Klaus Edvardsen

The average of price targets set by Wall Street analysts indicates a potential upside of 53.3% in CureVac N.V. (CVAC). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts See a 53% Upside in CureVac N.V. (CVAC): Can the Stock Really Move This High?

CureVac is broadening its foundation in oncology, leveraging recent progress with its second-generation mRNA backbone The partnership combines CureVac's mRNA technology with myNEO's platform for the discovery and selection of tumor antigens predicted to elicit strong immune responses Together with myNEO, CureVac aims to identify specific antigens for the development of novel mRNA cancer vaccines TÜBINGEN, GERMANY and GHENT, BELGIUM / ACCESSWIRE / May 25, 2022 / CureVac N.V. (Nasdaq:CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), and myNEO N.V.

CureVac Partners with myNEO to Identify Novel Antigen Targets for mRNA-Based Cancer Vaccine Development

Progressing broad vaccine development program in collaboration with GSK, with second-generation candidates in Phase 1 clinical trials for COVID-19 and influenza CureVac eligible to a €10 million milestone payment from GSK for the initiation of the influenza clinical trial Increasing momentum in oncology with access to neoantigen technologies to feed meaningful pipeline of cancer vaccine candidates Partnership with myNEO to develop novel mRNA cancer vaccines leveraging myNEO's advanced platform for tumor antigen discovery and selection Cash position of €658.2 million as of March 31, 2022, impacted by wind-down costs for first-generation COVID-19 vaccine program TÜBINGEN, GERMANY and BOSTON MA / ACCESSWIRE / May 25, 2022 / CureVac N.V. (Nasdaq:CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced financial results for the first quarter of 2022 and provided a business update.

Curevac Announces Financial Results For The First Quarter Of 2022 And Provides Business Update

CureVac NV (NASDAQ:CVAC ) Q4 2021 Earnings Conference Call April 28, 2022 9:00 AM ET Company Participants Sarah Fakih - VP Corporate Communications & IR Franz-Werner Haas - CEO Klaus Edvardsen - Chief Development Officer Pierre Kemula - CFO Conference Call Participants Douglas Buchanan - JMP Securities Eun Yang - Jefferies Zhiqiang Shu - Berenberg Operator Greetings. Welcome to the CureVac Fourth Quarter and Full Year 2021 Financial Results and Business Update Conference Call.

CureVac NV (CVAC) CEO Franz-Werner Haas on Q4 2021 Results - Earnings Call Transcript

- Executing on broad vaccine development program, with new clinical studies in COVID-19 and influenza together with GSK to validate advanced second-generation mRNA backbone - Initiated Phase 1 dose-escalation study in COVID-19 with CV2CoV, validating mRNA backbone for further variant adaptation - Fully recruited Phase 1 dose-escalation study in influenza with differentiated multivalent vaccine candidate, CVSQIV, confirmed good tolerability profile across all doses - Bivalent approach for combined Beta/Delta-COVID-19 vaccine candidate shows promising preclinical data, with high neutralizing capacity against each variant, as well as against Omicron - Increasing momentum in oncology pipeline by focusing on new avenues for T cell activation as well as access to novel classes of antigens and antigen discovery platforms - Launched fully owned subsidiary, CureVac RNA Printer GmbH, to accelerate development of The RNA Printer(R) with dedicated infrastructure and experienced management - Executed contract with German government for pandemic preparedness together with GSK, providing access to developed vaccines and CureVac's manufacturing capacity - Cash position of €811.5 million as of December 31, 2021. EU confirms no obligation to repay upfront payment for Advanced Purchase Agreement for first-generation candidate, CVnCoV TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / April 28, 2022 / CureVac N.V.

CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2021 and Provides Business Update

TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / April 22, 2022 / CureVac N.V. (NASDAQ:CVAC), a biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), will report financial results, and provide business updates for the fourth quarter and full-year 2021 on Thursday, April 28, 2022.

CureVac to Report Fourth Quarter and Full-Year 2021 Financial Results and Business Updates on April 28, 2022

- Vaccine candidate combining Beta- and Delta-specific mRNAs shows strong protection and immune responses during preclinical challenge study - Demonstrated neutralizing capacity against the Omicron variant in vaccinated animals - Technology adaptation for bivalent approach for COVID-19 vaccines potentially allows for broader protection against emerging variants TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / April 21, 2022 / CureVac N.V. (NASDAQ:CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced preclinical data demonstrating immune responses and protective efficacy of a bivalent second-generation COVID-19 vaccine candidate jointly developed with GSK, combining two mRNAs encoding for the Beta and the Delta variant.

CureVac and GSK's Bivalent Second-Generation mRNA Vaccine Candidate Shown to be Highly Effective Against SARS-CoV-2 Variants in Preclinical Study

GlaxoSmithKline

Shares of CureVac CVAC, -0.28% were up 0.6% in premarket trading on Monday after the company and GlaxoSmithKline GSK, +0.89% said they signed an agreement with the German government for pandemic preparedness that includes mRNA vaccines. As part of the agreement, Germany has access to CureVac's mRNA manufacturing until 2029.

CureVac, GSK ink 'pandemic preparedness' agreement through 2029 with German government

- German government reserves domestic manufacturing capacity until 2029 to ensure rapid access to mRNA vaccines developed by CureVac and GSK - Five-year contract enables production of up to 80 million vaccine doses at short notice in case of a public health emergency, contributing to increased pandemic preparedness TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / April 11, 2022 / CureVac N.V. (NASDAQ:CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), and GSK today announced that they have entered into a contract with the German federal government to supply mRNA vaccines within a broader tender for pandemic preparedness in Germany.

CureVac and GSK Enter into Pandemic Preparedness Contract with German Government

Shares of CureVac CVAC, +0.47% were up 1.2% in premarket trading on Wednesday after the company said it dosed the first participant in a Phase 1 clinical trial for the new mRNA COVID-19 vaccine it's developing with GlaxoSmithKline GSK, -0.18% . The study is being conducted in the U.S. and is set to enroll 210 adults.

CureVac begins Phase 1 clinical trial for new COVID-19 vaccine

Phase 1 dose-escalation study started at clinical sites in the U.S. Milestone demonstrates CureVac's and GSK's continued execution on comprehensive clinical program of second-generation vaccine candidates for infectious diseases TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / March 30, 2022 / CureVac N.V. (Nasdaq:CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced that the first participant was dosed in a Phase 1 study of COVID-19 second-generation mRNA vaccine candidate, CV2CoV, developed in collaboration with GSK.

CureVac and GSK Start Clinical Development of Second-Generation COVID-19 Vaccine Candidate, CV2CoV

The RNA Printer (R) is CureVac's integrated and automated manufacturing solution for RNA vaccines and therapeutics CureVac RNA Printer GmbH to provide dedicated infrastructure to accelerate development and broaden application range of The RNA Printer (R) Dr. Markus Bergmann appointed as General Manager for CureVac RNA Printer GmbH TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / March 1, 2022 / CureVac N.V. (NASDAQ:CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced that it has established CureVac RNA Printer GmbH, a fully-owned CureVac company to advance The RNA Printer(R).

CureVac Establishes Fully-Owned Company Dedicated to Advancing The RNA Printer(R)

CureVac (CVAC) doses the first patient in a phase I study with investigational influenza vaccine candidate.

CureVac (CVAC) Begins Influenza Shot Dosing in Phase I Study

- Multivalent technology approach for seasonal influenza mRNA vaccine candidate addressing four different influenza strains - Influenza candidate developed in collaboration with GSK within broad infectious disease vaccine program TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / February 10, 2022 / CureVac N.V. (NASDAQ:CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced that it has dosed the first participant in a Phase 1 study of its seasonal influenza second-generation mRNA vaccine candidate, CVSQIV, developed in collaboration with GSK.

CureVac Doses First Participant in Phase 1 Study with Multivalent Influenza Vaccine Candidate Based on Second-Generation mRNA Backbone Developed in Collaboration with GSK

Shares of CureVac CVAC, +5.06% gained 2.6% in premarket trading on Thursday after the company said it began dosing participants in a Phase 1 clinical trial assessing an experimental mRNA-based influenza vaccine it developed with GlaxoSmithKline GSK, -2.12% . The open-label study plans to enroll 240 adults.

CureVac starts Phase 1 trial for experimental flu shot developed with GSK

Shares of CureVac N.V. (NASDAQ: CVAC) closed nearly 15% down on Friday after BofA Securities said there isn't much in the books this year for shareholders of the German biopharmaceutical company.

BofA Securities: there's hardly any upside in CureVac this year

Amid broadly bearish market sentiment, investors in CureVac and CVAC stock are in selling mode, as this stock receives a downgrade. The post CVAC Stock Alert: Why Is Vaccine Maker CureVac Plunging Today?

CVAC Stock Alert: Why Is Vaccine Maker CureVac Plunging Today?

There is limited upside from CureVac BV's (NASDAQ:CVAC) COVID-19 vaccine and there are few catalysts from the rest of the company's pipeline in 2022, according to BofA Securities. The CureVac Analyst: Geoff Meacham downgraded the rating for CureVac from Neutral to Underperform, while reducing the price target from $55 to $20.

BofA Downgrades CureVac On Limited 2022 Prospects

TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / January 17, 2022 / CureVac N.V. (NASDAQ:CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced that the company's Chief Technology Officer, Dr. Mariola Fotin-Mleczek, will resign from CureVac effective January 31, 2022.

CureVac Chief Technology Officer to Pursue New Career outside Biotech Industry

Revisions to a shareholder agreement are causing the German vaccine maker's shares to fall.

Why CureVac Stock Is Sinking Today

BERLIN, GERMANY / ACCESSWIRE / January 13, 2022 / Today dievini and the Federal Republic of Germany announced the signing of a supplement to the shareholders' agreement between Kreditanstalt für Wiederaufbau (KfW) and the investment company dievini Hopp BioTech holding GmbH & Co. KG (dievini), DH-LT-Investments GmbH, and Dietmar Hopp related to their common shares in CureVac N.V. (CureVac) (NASDAQ:CVAC).

dievini and the Federal Republic of Germany Amend Shareholders' Agreement Regarding Investments in CureVac N.V.

Ahead of J.P. Morgan Healthcare Conference, CureVac BV (NASDAQ: CVAC) outlined the timeline for its vaccine programs.

CureVac Outlines Upcoming Catalysts For Vaccine Programs

Werner Enterprises

CureVac's (CVAC) CEO Franz-Werner Haas on Q3 2021 Results - Earnings Call Transcript

News for CureVac B.V Stock (CVAC)